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Volume 56, Number 6 Abstracts 1811Spray-Applied Cell Therapy With Human Allogeneic Fibroblasts and
Keratinocytes for the Treatment of Chronic Venous Leg ulcers: A
Phase 2, Multicentre, Double-Blind, Randomised, Placebo-Controlled
Trial
Kisner RS, Marston WA, Snyder RJ, et al. Lancet 2012;380:977-85.
Conclusion: Venous ulcers can be healed with a spray formulation of
allogeneic neonatal keratinocytes and fibroblasts without the need for tissue
engineering.
Summary: Venous insufficiency results from venous valve dysfunction
or venous obstruction, or both, of the superficial or deep veins. Subsequent
venous hypertension results in edema, tissue inflammation, and microcircu-
latory destruction. The end result can be a venous ulcer that can be
notoriously difficult to heal, with many not responding to standard com-
pression therapy. Surgery can result in reduced recurrence of venous ulcer-
ation, but no interventions on veins themselves have been shown to speed
healing of chronic venous ulcers (Barwell JR, et al, Lancet 2004;363:1854-
9). Nonsurgical therapies for venous ulceration have used tissue constructs
of allogeneic adult keratinocytes. Such tissue constructs are fragile and have
required incorporation of one or more dermis-like substitutes for delivery of
the keratinocytes to the wound. In a large randomized controlled trial,
repeated application of a tissue construct demonstrated an improvement in
venous ulcer healing compared with standard compression therapy (Falanga
V, Arch Dermatol 1998;134;293-300). However, allogeneic cells do not
engraft. It is therefore unclear if an elaborate tissue construct is actually
needed. HP802-247 is composed of cryopreserved allogeneic growth-
arrested fibroblasts and keratinocytes derived from neonatal foreskin (Goed-
koop R, Dermatol 2010;220:114-20). Success of foreskin-derived alloge-
neic keratinocytes in a two-component fibrin glue suggest that these cells can
deliver essential growth factors to a nonhealing wound without the need for
an elaborate tissue construct. In this study, the authors delivered growth-
arrested allogeneic neonatal keratinocytes and fibroblasts to nonhealing
venous ulcers using a spray, without an elaborate tissue construct. Outpa-
tients from 28 centers in the United States and Canada with up to three
ulcers, venous reflux confirmed by duplex ultrasound imaging and sufficient
arterial flow for healing were randomized in a phase 2, double-blind,
placebo-controlled trial. The study required that one ulcer measure between
2 and 12 cm in area and had persisted for 6 to 104 weeks. Randomization
was by computer-generated block method in a 1:1:1:1:1 ratio to 5.0  105
cells/mL every 7 days or every 14 days, or 0.5 105 cells/mL every 7 days
or every 14 days, or to vehicle alone every 7 days. All experimental groups
received four-layer compression bandages. Trial monitors, trial sponsors,
investigators, center personal, and patients were all masked to treatment
allocation. The primary end point was the mean percentage change in
wound area at the end of 12 weeks. Analysis was by intention to treat. There
were 45 patients assigned to 5.0 105 cells/mL every 7 days, 44 patients to
5.0 105 cells/ mL every 14 days, 43 patients to 0.5 105 cells/mL every
7 days, 46 patients to 0.5  105 cells/mL every 14 days, and 50 patients to
vehicle alone. There were 205 patients who completed all required study
visits. Primary outcome analysis demonstrated greater mean reduction in
wound area associated with active treatment compared with vehicle (P 
.0446), with the dose of 0.5  105 cells/mL every 14 days showing the
largest improvement compared with vehicle (15.98%, 95% confidence inter-
val, 5.56-26.41; P  .0028). Adverse events were the same in all groups,
with new skin ulcers and cellulitis occurring in 5% of patients.
Comment: This was a large well-conducted randomized trial suggest-
ing benefit in healing of venous leg ulcers with a spray application of
allogeneic cells. This study, combined with previous work, suggests alloge-
b
beic cell therapy for venous leg ulcers is likely to be effective. A larger study
f the optimum dose of HP802-247 compared with standard therapy for
enous leg ulcers seems indicated.
ystematic Review and Meta-Analysis of Vein Cuffs for Below-Knee
ynthetic Bypass
wine CP, Williams IM, Figelstone LJ. Br J Surg 2012;99:1195-202.
Conclusion: There is a small but significant benefit for vein cuffs in
onjunction with synthetic grafts used for femoral to below-knee popliteal
nastomoses. There is little benefit for more distal anastomoses.
Summary: The TransAtlantic Inter-Society Consensus (TASC) for the
anagement of Peripheral Arterial Disease guidelines advocate use of vein
uffs for bypass grafts of synthetic material to infrageniculate arteries. Evi-
ence favoring use of vein cuffs for polytetrafluroethylene (PTFE) infrain-
uinal grafts comes primarily from case series. One randomized trial from
he Joint Vascular Research Group did show a significant benefit in the favor
f vein cuffs for below-knee bypasses (Stonebridge PA, et al, Vasc Surg
997;26:543-50). However, a more contemporary randomized study, the
candinavian Miller Cuff Study (SCAMICOS) showed no benefit for vein
uffs as adjuncts to below-knee synthetic grafts (SCAMICOS, Eur J Vasc
ndovasc Surg 2010;39:747-54). There has also been a Cochrane Review
n the use on vein cuffs, but it was performed without the SCAMICOS data
Cochrane Database Syst Rev 2010;CD001487). The authors note that a
eta-analysis of all available data has not been performed on the use of vein
uffs to enhance patency of synthetic below-knee bypass grafts. They sought
o combine the results of the two major randomized trials with pertinent
ohort studies to provide the most complete estimate on the use of vein cuffs
s adjuncts to synthetic grafts to below-knee arteries. The authors identified
hree cohort and two randomized studies for inclusion in their meta-analysis.
his involved an analysis of data from 885 patients. That analysis was
reformed according to recommendations of the Cochrane Collaboration,
nd the PRISMA guidelines (Liberati A, et al, PLoSMed 2009;6:e1000100;
nd Higgins JPT et al, Cochrane handbook for systematic reviews of
nterventions, version 5.0.2., Chicester: John Wiley & Sons; 2010). Non-
andomized studies were included in the review if they had sufficient quality
s assessed by the Newcastle-Ottawa scale. In this study, analysis was
ltimately carried out on 483 patients with cuff grafts and 402 with no cuff.
nalysis was divided into below-knee popliteal (377 cuffed, 279 uncuffed)
nd distal (106 cuffed, 123 uncuffed) grafts. Graft material was PTFE in all
ases. Follow-up was limited to 3 years. Analysis for below-knee popliteal
ypasses showed a significant improvement in primary patency for cuffed
rafts at 2 years, but not at 1 or 3 years (odds ratio at 2 years, 0.46; 95%
onfidence interval, 0.22-0.97; P  .04). Limb salvage was significantly
mproved in cuffed grafts up to 2 years. For more distal grafts, cuffs did not
rovide any improvement in primary patency at any time interval. However,
t did appear that limb salvage was improved for cuffed distal grafts at 2 years
odds ratio, 0.29; 95% confidence interval, 0.11-0.75; P  .01). There was
o significant difference at any other time interval.
Comment: A reasonable conclusion from this study is that there is a
mall benefit for using vein cuffs as adjuncts to PTFE grafts to the below-
nee popliteal artery. There is minimal to no benefit to the use of a vein cuff
s an adjunct to a PTFE graft to a tibial vessel. However, it does not appear
hat a vein cuff, under any circumstances, worsens outcomes. Vein cuffs can
e safely used at the discretion of the operating surgeon even for synthetic
ypasses to tibial vessels.
